Analysis of Red Blood Cell Integrity and Efficiency of Recovery Using a Novel Surgical Sponge-Blood Recovery Device (ProCell)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-20

Study Completion Date

2026-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to compare two methods of recovering blood from surgical sponges used during heart and lung surgeries. The two methods are: 1) manually wringing sponges by hand, and 2) automated wringing sponges by an FDA approved suction device. Both methods are already in use in heart and lung surgeries at University Hospitals at the discretion of the surgeon.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Analysis of Red Blood Cell Integrity and Efficiency of Recovery Using a Novel Surgical Sponge-Blood Recovery Device (ProCell): Delayed Impact

NCT05545956

Blood Recovery

WITHDRAWN NA

Obtaining and Storing Blood Samples and Debridement Samples for Wound Related Research

NCT00762697

Venous Insufficiency

COMPLETED

Negative Pressure Wound Therapy in Post-Operative Incision Management

NCT02682316

Negative-Pressure Wound Therapy

COMPLETED PHASE3

Post-Market Clinical Evaluation of the Spiracur SNaP Wound Care System for Treatment of Acute Trauma and Acute Surgical Excision Wounds

NCT01417234

COMPLETED

Transcutaneous Oxygen as a Predictor of Wound Healing Complications in Preoperatively Radiated Soft Tissue Sarcoma

NCT02897128

Sarcoma, Soft Tissue

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Blood Recovery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Participants

Subjects will be blinded to the order of intervention.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hand Wrung

Hand wrung refers to manually wringing surgical sponges by hand.

Group Type ACTIVE_COMPARATOR

Hand Wrung

Intervention Type PROCEDURE

Hand wrung refers to manually wringing surgical sponges by hand.

ProCell Wrung

ProCell wrung refers to automated wringing surgical sponges by an FDA approved suction device (ProCell).

Group Type EXPERIMENTAL

ProCell Wrung

Intervention Type DEVICE

ProCell wrung refers to automated wringing surgical sponges by an FDA approved suction device (ProCell).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hand Wrung

Hand wrung refers to manually wringing surgical sponges by hand.

Intervention Type PROCEDURE

ProCell Wrung

ProCell wrung refers to automated wringing surgical sponges by an FDA approved suction device (ProCell).

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Undergoing heart or lung transplant, redo sternotomy, aortic surgery, and/or multi-valve repairs/replacements; and
* At University Hospitals Cleveland Medical Center.

Exclusion Criteria

* Patients with known bleeding disorders, including disseminated intravascular coagulation (DIC), prothrombin deficiency, factor V deficiency, factor VII deficiency, factor X deficiency, factor XI deficiency (hemophilia C), Glanzmann disease, hemophilia A, hemophilia B, idiopathic thrombocytopenic purpura (ITP), and Von Willebrand disease (types I, II, and III);
* Patients undergoing emergent or emergent salvage surgery; and
* Patients actively participating in another clinical trial which could affect outcomes.

Minimum Eligible Age

18 Years

Maximum Eligible Age

89 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No